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1. INTRODUCTION {#jdb12928-sec-0005}
===============

Diabetic retinopathy (DR) is a common and serious microvascular complication of type 2 diabetes (T2D) and a leading cause of blindness among the working‐age population in developed countries.[1](#jdb12928-bib-0001){ref-type="ref"} As an initial treatment, intensive glycemic treatment has been shown to delay the onset and progression of DR. As subsequent treatments, both oral antidiabetic drugs (OADs) alone and basal insulin‐supported OADs therapy (BOT) are frequently administered to T2D patients. However, it remains unclear which subsequent treatment has the best effect on DR. Furthermore, it is debatable whether insulin treatment is beneficial or harmful with regard to DR. Traditionally, proliferative DR is an indication for insulin therapy, indicating that insulin is superior to OADs in treating diabetic patients with DR. However, some recent reports have claimed that insulin therapy is harmful to DR.[2](#jdb12928-bib-0002){ref-type="ref"}, [3](#jdb12928-bib-0003){ref-type="ref"}, [4](#jdb12928-bib-0004){ref-type="ref"}, [5](#jdb12928-bib-0005){ref-type="ref"}, [6](#jdb12928-bib-0006){ref-type="ref"} Thus, the primary aim of this randomized controlled trial was to compare the effects of OADs and BOT as subsequent therapies on DR.

Favorable overall glycemic control is necessary to prevent the onset and progression of DR.[7](#jdb12928-bib-0007){ref-type="ref"} Currently, glycemia comprises not only general glycemia, which is represented by HbA1c, but also glycemic stability, which is also called glycemic variability (GV). Because inflammation contributes to mechanisms underlying the occurrence and deterioration of DR, the secondary objective of this study was to compare the effects of these OADs alone and BOT on glycemia and inflammation.

2. METHODS {#jdb12928-sec-0006}
==========

2.1. Study design and patients {#jdb12928-sec-0007}
------------------------------

This study was a single‐center prospective randomized open‐label trial conducted at the Third Affiliated Hospital of Sun Yat‐sen University between January 2015 and January 2018. The study was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat‐sen University and the study is registered with <http://clinicaltrials.gov> (ID NCT02587741). Written informed consent was obtained from all participants.

The inclusion criteria were as follows: T2D diagnosis according to the 1999 World Health Organization criteria,[8](#jdb12928-bib-0008){ref-type="ref"} age 18 to 65 years, body mass index (BMI) 20 to 35 kg/m^2^, duration of diabetes 0 to 5 years, and HbA1c \>7.0%. Patients with a history of macrovascular disease (including ischemic heart disease, heart failure, and cerebrovascular disease), acute diabetic complications in the previous 6 months, diabetic microvascular complications, hepatic or renal impairment, malignant tumors, autoimmune diseases, and acute or chronic infections were excluded from the study, as were pregnant and lactating women.

2.2. Study protocol {#jdb12928-sec-0008}
-------------------

The study process is shown in Figure [1](#jdb12928-fig-0001){ref-type="fig"}. Data for all eligible patients were collected via paper‐based case report forms and included information on baseline characteristics (sex, age, duration of diabetes, previous medical history, medications etc.) and anthropometric data (body weight, height, BMI, heart rate, and blood pressure). Urinary albumin was measured in three consecutive 24‐hour urine collections using a turbidimetric immunoassay and is expressed as the urine albumin excretion rate (UAER). For biochemical analysis, blood samples were drawn after an 8‐hour overnight fast. Laboratory assessments consisted of fasting blood glucose (FBG) concentrations, 2‐hour postprandial blood glucose (2hPBG) concentrations, liver function, renal function, lipid profiles, and electrolytes, which were measured using a HITACHI (Tokyo, Japan) 7180 Automatic Analyzer. C‐peptide and insulin were determined by radioimmunoassay (Beijing Bio‐Ekon Biotechnology, Beijing, China), whereas HbA1c was measured using the D‐10 Hemoglobin Testing System (Bio‐Rad Laboratories, Hercules, California). Serum concentrations of interleukin (IL)‐1β, IL‐6, and IL‐17α were determined using the Human Cytokine/Chemokine Magnetic Bead Panel Kit (Asbio Technology, Guangzhou, China). Eye examinations comprised visual acuity testing, tonometry, and retinal exploration. Evaluation of the retina was made by SLM‐JER slit‐lamp biomicroscopy (Chongqing Kanghua, Chongqing, China) of the posterior pole using contact lenses after pupil dilation with tropicamide 0.5% and phenylephrine HCl 10% eye drops. Retinal angiography was tested by APS‐GER digital fundus photography (Chongqing Kanghua, Chongqing, China) after intravenous injection of 10% fluorescein. Diabetic retinopathy was graded according to the International Classification of Diabetic Retinopathy.[9](#jdb12928-bib-0009){ref-type="ref"} Diabetic retinopathy was diagnosed in the Department of Ophthalmology of the 3rd affiliated hospital of Sun Yat‐sen university by a single specialist, who was blinded to the treatments.

![ Study design. OADs, oral antidiabetic drugs; BOT, basal insulin‐supported OADs therapy; FBG, fasting blood glucose; 2hPBG, 2‐hours postprandial blood glucose](JDB-11-949-g001){#jdb12928-fig-0001}

All eligible patients entered a 14‐day intensive insulin treatment lead‐in period. During the lead‐in period, continuous subcutaneous insulin infusion was performed to achieve the glycemic target, which was defined as both FBG 4.4 to 5.6 mM and 2hPBG \<7.8 mM. Then, participants were randomized in a ratio of 1:  1 to either BOT or OADs as the subsequent treatment. Sealed opaque envelopes, which were arranged in a computer‐generated random order prepared by a statistician prior to the study, were opened to determine the patients\' treatment assignment.

2.3. Treatments {#jdb12928-sec-0009}
---------------

### 2.3.1. Oral antidiabetic drugs {#jdb12928-sec-0010}

The OADs that patients received were determined by the physicians as part of routine clinical care. The algorithm for OAD selection was one OAD from the minimum dose to the maximum dose, sequentially supplemented with additional OADs until the glucose target was achieved. The order of selection of OADs was: metformin (Glucophage; Bristol‐Myers Squibb, Shanghai, China), gliclazide (Diamicron; Servier, Tianjin, China), α‐glucosidase inhibitor (acarbose; Bayer, Shanghai, China), and a dipeptidyl peptidase (DPP)‐4 inhibitor (Januvia; Merck Sharp & Dohme, Shanghai, China).

### 2.3.2. Basal insulin‐supported OADs therapy {#jdb12928-sec-0011}

Insulin glargine (Lantus; Sanofi‐Aventis, Shanghai, China) was administered initially at a dose of 0.2 IU/kg. The dose was then adjusted according to Table [1](#jdb12928-tbl-0001){ref-type="table"}. The OADs were supplemented if the glycemic target was not achieved or maintained. The OADs were prescribed in accordance with the algorithm used for the OAD group.

###### 

 Algorithm for insulin dose adjustment

  Fasting blood glucose (mM)   Insulin dose adjustment
  ---------------------------- -------------------------
  \<4.4                        Decrease dose by 2 IU
  4.4‐5.6                      No adjustment required
  5.6‐8.0                      Increase dose by 2 IU
  8.0‐10.0                     Increase dose by 4 IU
  \>10.0                       Increase dose by 6 IU

2.4. Outpatient follow‐up and outcome assessment {#jdb12928-sec-0012}
------------------------------------------------

Fasting blood glucose, 2hPBG, and HbA1c values were collected every 3 months. All subjects were monitored using a continuous glucose monitoring system (MiniMed Paradigm 722; Medtronic, Northridge, California, USA) for three consecutive days at the time of randomization and at the12‐month follow‐up. At the same time, eye examinations were performed and UAER was measured. Blood samples were also collected to measure markers of inflammation. Anthropometric information, medications, self‐monitored blood glucose, hypoglycemia events, and adverse events were recorded at every follow‐up visit.

2.5. Glycemic control {#jdb12928-sec-0013}
---------------------

The glycemic control in this study comprised both HbA1c to target and GV. The target HbA1c was ≤7%, and achieving this target was defined as HbA1c remission. In the present study, long‐term GV was evaluated by the standard deviation (SD) and coefficient of variation (CV) of FBG and HbA1c. The short‐term intraday GV was evaluated by the SD of blood glucose (SDBG) and the mean amplitude of glycemic excursions (MAGE). The short‐term interday GV was evaluated by the mean of daily differences (MODD), which was calculated from the mean absolute value of differences between glucose values on two consecutive days at the same time point.

2.6. Statistical analysis {#jdb12928-sec-0014}
-------------------------

All statistical analyses were performed using PASW statistics 19.0 (IBM Corp., Armonk, New York, USA). Continuous variables are presented as the mean ± SD, whereas categorical variables are expressed as percentages. Differences in continuous variables between groups were evaluated using Student\'s *t* tests, whereas differences in categorical variables were evaluated by Pearson\'s χ^2^ tests. Two‐sided *P* \< 0.05 was considered significant.

3. RESULTS {#jdb12928-sec-0015}
==========

3.1. Characteristics of study subjects {#jdb12928-sec-0016}
--------------------------------------

In all, 290 subjects were recruited in this study after the initial screening. Of these, 148 were randomly assigned to the OAD group and the remaining 142 were assigned to the BOT group. Four subjects in the OAD group and 10 in the BOT group were lost to follow‐up, all of which were in euglycemic remission during their last documented study visit (Figure [2](#jdb12928-fig-0002){ref-type="fig"}). At baseline, no characteristics differed significantly between the OAD and BOT groups (*P \>* 0.05). At the 12‐month follow‐up, UAER was significantly higher in the OAD than BOT group (*P \<* 0.05); there were no significant differences in any other parameters between the two groups (*P \>* 0.05; Table [2](#jdb12928-tbl-0002){ref-type="table"}).

![ Study flow chart. OAD, oral antidiabetic drug; BOT, basal insulin‐supported OAD therapy](JDB-11-949-g002){#jdb12928-fig-0002}

###### 

Characteristics of all participants at baseline and at the 12‐month follow‐up

                                               Baseline             12‐month follow‐up                                                  
  -------------------------------------------- -------------------- -------------------- ---- -------------------- -------------------- -------
  Age (y)                                      50.1 ± 6.7           51.7 ± 7.1           NS   ‐                    ‐                    ‐
  No. males/females                            83/61                78/54                NS   ‐                    ‐                    ‐
  Diabetes duration (y)                        2.3 ± 1.5            2.4 ± 2.0            NS   ‐                    ‐                    ‐
  SBP (mm Hg)                                  134.1 ± 15.4         137.0 ± 20.2         NS   130.2 ± 18.6         122.4 ± 32.3         NS
  DBP (mm Hg)                                  85.2 ± 11.9          84.4 ± 11.7          NS   79.6 ± 8.6           80.5 ± 9.4           NS
  Weight (kg)                                  66.08 ± 10.86        67.59 ± 10.59        NS   65.66 ± 11.00        67.30 ± 9.95         NS
  BMI (kg/m^2^)                                25.32 ± 2.97         25.31 ± 2.91         NS   24.47 ± 4.26         24.53 ± 2.66         NS
  WC (cm)                                      85.97 ± 7.72         88.00 ± 9.38         NS   84.58 ± 9.82         87.81 ± 8.86         NS
  FCP (pM)                                     1.68 ± 0.63          1.94 ± 1.88          NS   1.86 ± 0.62          1.56 ± 1.22          NS
  2 h‐PCP (pM)                                 5.02 ± 1.97          4.19 ± 2.68          NS   5.84 ± 2.29          4.98 ± 3.71          NS
  Cr (μM)                                      57.90 ± 20.33        58.12 ± 20.09        NS   64.16 ± 17.58        65.83 ± 20.47        NS
  UA (μM)                                      303.58 ± 71.26       313.95 ± 84.90       NS   357.31 ± 69.42       335.62 ± 74.11       NS
  TC (mM)                                      6.09 ± 1.58          5.59 ± 1.55          NS   5.38 ± 1.12          5.29 ± 1.21          NS
  Median \[25th to 75th percentile\] TG (mM)   2.72 \[1.31‐4.44\]   2.84 \[1.34‐3.77\]   NS   1.88 \[0.83‐2.32\]   1.58 \[0.86‐1.79\]   NS
  HDL‐C (mM)                                   1.48 ± 0.53          1.38 ± 0.21          NS   1.71 ± 0.71          1.64 ± 0.57          NS
  LDL‐C (mM)                                   3.48 ± 0.77          3.27 ± 0.96          NS   2.86 ± 0.74          2.88 ± 0.93          NS
  Cystatin C (μM)                              0.80 ± 0.27          0.85 ± 0.39          NS   0.65 ± 0.07          0.66 ± 0.40          NS
  UAER (μg/min)                                5.22 ± 4.78          6.77 ± 5.34          NS   11.03 ± 8.63         5.45 ± 4.15\*        0.012

Unless indicated otherwise, data are given as the mean ± SD unless.

OAD, oral anti‐diabetic drug; BOT, basal insulin‐supported OADs therapy; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; WC, Waist circumference; FCP, Fasting C‐peptide; 2 h‐PCP, 2 hour ‐postprandial C‐peptide; Cr, plasma creatinine; UA, uric acid; TC, total cholesterol; TG, triglycerides; HDL‐C, high density lipoprotein cholesterol; LDL‐C, low density lipoprotein cholesterol; UAER, urine albumin excretion rate.

3.2. Incidence of DR {#jdb12928-sec-0017}
--------------------

At the 12‐month follow‐up, fewer patients had developed DR in the BOT than OAD group (8 \[6.06%\] vs 12 \[8.3%\]; *P* = 0.034\]. The DR that developed during the follow‐up period was non‐proliferative. No diabetic macular edema was detected in any participant.

3.3. Glycemic control and HbA1c remission during follow‐up {#jdb12928-sec-0018}
----------------------------------------------------------

The results of FBG, 2hPBG, and HbA1c monitoring during the 12‐month follow‐up period are shown in Figure [3](#jdb12928-fig-0003){ref-type="fig"}A--C. At baseline, there were no significant differences in FBG, 2hPBG, or HbA1c between the two groups (*P \>* 0.05). At the 3rd month, FBG, 2hPBG, and HbA1c were higher in the BOT than OAD group (*P \<* 0.05). However, at both the 6th and 12th month, FBG, 2hPBG, and HbA1c were all lower in the BOT than OAD group (*P \<* 0.05).

![ Glycemic control and proportion of patients reaching target HbA1c ≤7% in groups treated with oral antidiabetic drugs (OADs) alone or basal insulin‐supported OAD therapy (BOT). Data are the mean ± SD. \**P* \< 0.05, \*\**P* \< 0.01 (Student\'s *t* test). FBG, fasting blood glucose; 2hPBG, 2‐hours postprandial blood glucose](JDB-11-949-g003){#jdb12928-fig-0003}

After 3 months of treatment, fewer patients had achieved the HbA1c target (≤7.0%) in the BOT than OAD group (63.6% \[84/132\] vs 72.2% \[104/144\], respectively; *P \<* 0.05). However, among those who achieved the HbA1c target at the 3rd month, fewer patients in the BOT than OADs group failed to maintain the target at the 6th month (n = 4 vs 8). This led to a similar HbA1c remission rate between the two groups at the 6th month (60.6% and 66.6%, respectively; *P \>* 0.05). At the 12th month, the HbA1c remission rate increased to 75.0% (99/132) in the BOT group, but declined further to 61.1% (88/144) in the OAD group. This difference was statistically significant (*P \<* 0.05; Figure [3](#jdb12928-fig-0003){ref-type="fig"}D).

3.4. Glycemic variability between the two groups {#jdb12928-sec-0019}
------------------------------------------------

With regard to long‐term GV, neither SD‐HbA1c nor CV‐HbA1c differed between the two groups (*P \>* 0.05), whereas both SD‐FBG and CV‐FBG were significantly lower in the BOT than OAD group (*P \<* 0.001). With regard to intraday GV, SDBG and MAGE were both significantly lower in the BOT than OAD group (*P \<* 0.05). With regard to interday GV, neither FGE nor MODD differed significantly between the two groups (*P \>* 0.05), as presented in Table [3](#jdb12928-tbl-0003){ref-type="table"}.

###### 

 Glycemic variability in the two groups at baseline and the 12‐month follow‐up

                                     Baseline      12‐month follow‐up                                           
  ---------------------------------- ------------- -------------------- ------- --------------- --------------- ---------
  Long‐term glycemic variability                                                                                
  SD‐HbA1c                           ‐             ‐                    ‐       0.404 ± 0.284   0.435 ± 0.264   NS
  CV‐HbA1c                           ‐             ‐                    ‐       0.061 ± 0.044   0.064 ± 0.038   NS
  SD‐FBG                             ‐             ‐                    ‐       1.183 ± 0.664   0.812 ± 0.587   \<0.001
  CV‐FBG                             ‐             ‐                    ‐       0.161 ± 0.079   0.110 ± 0.071   \<0.001
  Intraday glycemic variability                                                                                 
  24‐hours mean glucose levels       7.77 ± 1.51   7.25 ± 1.00          0.003   7.64 ± 1.26     7.33 ± 2.15     NS
  SDBG                               1.76 ± 0.50   1.60 ± 0.78          NS      2.00 ± 0.96     1.62 ± 0.97     0.006
  \% CV of 24‐hours glucose levels   0.23 ± 0.05   0.22 ± 0.10          NS      0.25 ± 0.09     0.23 ± 0.12     NS
  MAGE                               3.04 ± 1.07   3.22 ± 1.72          NS      3.60 ± 1.47     3.18 ± 1.51     0.049
  FGE                                3.70 ± 1.55   3.45 ± 1.37          NS      3.86 ± 1.64     3.50 ± 1.56     NS
  Interday glycemic variability                                                                                 
  MODD                               2.20 ± 1.24   2.33 ± 1.21          NS      2.32 ± 1.45     2.47 ± 1.43     NS

Data are given as the mean ± SD.

BOT, basal insulin‐supported oral antidiabetic drug (OAD) therapy; CV‐FBG, coefficient of variation of fasting blood glucose; CV‐HbA1c, coefficient of variation of HbA1c; FGE, frequency of glucose excursion; MAGE, mean amplitude of glycemic excursions; MODD, mean of daily differences; SD‐FBG, standard deviation of fasting blood glucose; SD‐HbA1c, standard deviation of HbA1c; SDBG, standard deviation of blood glucose.

3.5. Inflammatory biomarkers {#jdb12928-sec-0020}
----------------------------

In the present study, IL‐1β, IL‐6, and IL‐17α were selected as inflammatory biomarkers. There were no significant differences in any of these cytokines at baseline or at the 12‐month follow‐up between the two groups (Figure [4](#jdb12928-fig-0004){ref-type="fig"}A). However, all changes in IL‐1β, IL‐6, and IL‐17α were significantly smaller in the BOT than OAD group (Figure [4](#jdb12928-fig-0004){ref-type="fig"}B).

![ A, Serum cytokine concentrations and B, changes in serum cytokine concentrations in patients receiving oral antidiabetic drugs (OADs) alone or basal insulin‐supported OAD therapy (BOT). A, There were no significant differences in serum concentrations of interleukin (IL)‐1β, IL‐6, or IL‐17α between the two groups at baseline or after 12 months. B, However, there were significant differences in changes in serum cytokine concentrations between the two groups. Data are the mean ± SD. \**P* \< 0.05, \*\**P* \< 0.01 versus OAD group (Student\'s *t* test)](JDB-11-949-g004){#jdb12928-fig-0004}

3.6. Adverse events {#jdb12928-sec-0021}
-------------------

There were no serious adverse events in either group. No significant changes in body weight were observed in either group (Table [2](#jdb12928-tbl-0002){ref-type="table"}). Similar rates of hypoglycemia were observed in the OAD and BOT groups (9.87% vs 10.71%, respectively; *P \>* 0.05).

4. DISCUSSION {#jdb12928-sec-0022}
=============

The results of the present study indicate that, as a subsequent treatment, the BOT regimen was associated with a reduced occurrence of DR than OADs alone at the 12‐month follow‐up. The BOT regimen maintained the HbA1c target longer than OADs alone, with similar rates of hypoglycemia. In addition, the BOT regimen reduced long‐term and intraday GV compared with OADs alone.

Our results regarding the reduction in the incidence of DR with basal insulin‐supplemented therapy agree with those of previous studies. A few reports have indicated that insulin treatment prevents or delays DR in type 1 diabetes (T1D).[10](#jdb12928-bib-0010){ref-type="ref"}, [11](#jdb12928-bib-0011){ref-type="ref"}, [12](#jdb12928-bib-0012){ref-type="ref"}, [13](#jdb12928-bib-0013){ref-type="ref"}, [14](#jdb12928-bib-0014){ref-type="ref"} A systematic review revealed that insulin treatment can also reduce DR in T2D, although the reduction was not as marked as that in T1D.[15](#jdb12928-bib-0015){ref-type="ref"} The findings of an experimental animal study also suggested that insulin treatment benefited DR.[16](#jdb12928-bib-0016){ref-type="ref"} However, some studies have suggested that insulin therapy could be harmful with regard to DR.[2](#jdb12928-bib-0002){ref-type="ref"}, [3](#jdb12928-bib-0003){ref-type="ref"}, [4](#jdb12928-bib-0004){ref-type="ref"}, [5](#jdb12928-bib-0005){ref-type="ref"}, [6](#jdb12928-bib-0006){ref-type="ref"} These inconsistent results imply that the relationship between insulin treatment and DR is complicated. Indeed, numerous factors contribute to this relationship, such as the duration of diabetes, HbA1c, background treatment, complications, accompanying diseases, β‐cell function, the timing and duration of insulin therapy, and the stage of DR. To the best of our knowledge, no investigation has compared the effects on DR of different regimens as subsequent therapies after intensive glycemic treatment. The findings of the present study suggest that BOT is superior to OADs alone as a subsequent therapy to prevent or delay DR, which implies that basal insulin supplementation benefited DR. Given that both BOT and OADs alone are widely used in clinical practice, further targeted studies are required.

Favorable overall glycemic control is necessary to prevent the onset of DR and to delay its progression.[7](#jdb12928-bib-0007){ref-type="ref"} Currently, HbA1c is considered the gold standard for general glycemic control and it has been shown to be closely related to diabetic complications, such as DR.[10](#jdb12928-bib-0010){ref-type="ref"}, [11](#jdb12928-bib-0011){ref-type="ref"}, [12](#jdb12928-bib-0012){ref-type="ref"}, [13](#jdb12928-bib-0013){ref-type="ref"}, [14](#jdb12928-bib-0014){ref-type="ref"}, [15](#jdb12928-bib-0015){ref-type="ref"} The results of the present study showed that HbA1c levels were lower in the BOT than OAD group at both the 6th and 12th month, although they were higher in the BOT than OAD group at the 3rd month. This result suggests that basal insulin supplementation provides a longer and better‐maintained glycemic target, resulting in a lower incidence of DR. Notably, glycemia includes not only HbA1c but also GV. Recently, GV has emerged as one of the components of glycemia.[17](#jdb12928-bib-0017){ref-type="ref"} The Diabetes Control and Complications Trial (DCCT) was the first study that suggested that GV should be considered. In the DCCT study, the DR risk was substantially lower in the intensive treatment group than in the conventional treatment group (6% vs 14%), although the HbA1c values were approximately 9% in both groups.[18](#jdb12928-bib-0018){ref-type="ref"} This difference was attributed to GV. Numerous later studies have further indicated that GV plays an important role in the development and progression of DM complications.[19](#jdb12928-bib-0019){ref-type="ref"}, [20](#jdb12928-bib-0020){ref-type="ref"}, [21](#jdb12928-bib-0021){ref-type="ref"}, [22](#jdb12928-bib-0022){ref-type="ref"}, [23](#jdb12928-bib-0023){ref-type="ref"}, [24](#jdb12928-bib-0024){ref-type="ref"} Hence, to prevent the occurrence of DR, optimized antidiabetic therapy should focus on not only HbA1c, but also GV. Glycemic variability is more complex than general glycemia. Unfortunately, there has been no gold standard to measure GV until now. Glycemic variability at a minimum includes long‐term GV, short‐term intraday GV, short‐term interday GV, and the incidence of hypoglycemia. In the present study, we used SD‐FBG, SD‐HbA1c, CV‐FBG, CV‐HbA1c, SDBG, MAGE, and MODD to represent GV. As shown in Table [3](#jdb12928-tbl-0003){ref-type="table"}, most of the indices of GV were lower in the BOT than OAD group. We therefore suggest that BOT can decrease glycemia more completely than OADs. At the same time, the incidence of hypoglycemia in the BOT group was similar to that in the OAD group. Overall, the BOT regimen decreased glycemia more effectively, stably, and completely than OADs without increasing hypoglycemia, which may contribute to its superiority in the prevention of DR.

Inflammation is a major pathogenic factor associated with DR.[25](#jdb12928-bib-0025){ref-type="ref"}, [26](#jdb12928-bib-0026){ref-type="ref"} Both general hyperglycemia and GV can induce and enhance inflammation.[27](#jdb12928-bib-0027){ref-type="ref"}, [28](#jdb12928-bib-0028){ref-type="ref"}, [29](#jdb12928-bib-0029){ref-type="ref"}, [30](#jdb12928-bib-0030){ref-type="ref"} Therefore, we compared the levels of selected cytokines between the two treatment regimens. Among the cytokines, IL‐1β, IL‐6, and IL‐17α have been reported to contribute greatly to DR,[31](#jdb12928-bib-0031){ref-type="ref"}, [32](#jdb12928-bib-0032){ref-type="ref"}, [33](#jdb12928-bib-0033){ref-type="ref"}, [34](#jdb12928-bib-0034){ref-type="ref"}, [35](#jdb12928-bib-0035){ref-type="ref"}, [36](#jdb12928-bib-0036){ref-type="ref"} although there is some controversy regarding this issue.[37](#jdb12928-bib-0037){ref-type="ref"}, [38](#jdb12928-bib-0038){ref-type="ref"} Thus, we measured these three cytokines in the present study. Unfortunately, none of the cytokines showed any differences between the two groups at the 12‐month follow‐up. Notably, the changes in serum concentrations of all cytokines between the 12‐month follow‐up and baseline differed significantly between the two treatment regimens. The only difference between the BOT and OADs regimens was basal insulin supplementation. Consequently, the differences in the changes in cytokines may be due to a direct anti‐inflammatory effect of insulin, which is independent of its hypoglycemic effect.[39](#jdb12928-bib-0039){ref-type="ref"}

Interestingly, UAER, which is usually used to screen for diabetic nephropathy (DN), decreased in the BOT group and increased in the OAD group at the 12‐month follow‐up. These results suggest that basal insulin supplementation also benefits DN. Given that both DN and DR are characteristic microvascular complications of T2D, the results indicate that basal insulin supplementation benefits the microvascular complications of diabetes.

This study had some limitations, the most important of which is that the follow‐up time was relatively short. Diabetic retinopathy is a chronic complication of diabetes that usually appears in patients with poorly controlled glycemia of a long duration. A 12‐month follow‐up may not be sufficient, which may have contributed to the fact that few DR cases occurred in either group (8/132 in the BOT group vs 12/144 in the OAD group) and that all cases of DR were non‐proliferative. Prospective studies with longer follow‐up periods are required to validate this 12‐month result. Because there were few cases of DR in the present study, the sample size appears to be relatively small, and hence studies with a larger sample size are needed. In this study, there were no differences in cytokine concentrations between the two groups at the 12‐month follow‐up. Consequently, the significance of differences in the changes in IL‐1β, IL‐6, and IL‐17α between the two regimens was relatively slight. Therefore, we cannot determine whether these three cytokines were responsible for the superiority of basal insulin supplementation. More in‐depth studies with expanded cytokine measurements are required to further investigate the mechanisms underlying the effects of BOT.

4.1. Conclusion {#jdb12928-sec-0023}
---------------

In conclusion, the findings of this study suggest that 12‐month basal insulin supplementation as a subsequent therapy decreases the incidence of DR in short‐duration T2D by reducing glycemia more effectively, stably, and completely.
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